S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
NASDAQ:IMTX

Immatics (IMTX) Stock Price, News & Analysis

$10.95
-0.15 (-1.35%)
(As of 12:40 PM ET)
Today's Range
$10.90
$11.22
50-Day Range
$11.10
$12.94
52-Week Range
$5.90
$13.16
Volume
108,290 shs
Average Volume
518,680 shs
Market Capitalization
$927.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Immatics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
8.9% Upside
$12.00 Price Target
Short Interest
Bearish
9.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Immatics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.65) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.40 out of 5 stars

Medical Sector

900th out of 939 stocks

Biological Products, Except Diagnostic Industry

150th out of 155 stocks

IMTX stock logo

About Immatics Stock (NASDAQ:IMTX)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTX Stock Price History

IMTX Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Cantor sees strong year ahead for oncology M&A
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Immatics Announces Proposed Public Offering
Analyzing Immatics' Multi-Faceted Investment Case
IMTX Oct 2023 10.000 put
Immatics shares rise on Moderna cancer collaboration
See More Headlines
Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMTX
Fax
N/A
Employees
433
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+8.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-104,980,000.00
Net Margins
-179.67%
Pretax Margin
-179.63%

Debt

Sales & Book Value

Annual Sales
$54.00 million
Book Value
$2.88 per share

Miscellaneous

Free Float
N/A
Market Cap
$939.68 million
Optionable
Optionable
Beta
0.69
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 49)
    CEO, MD, Member of Management Board & Executive Director
    Comp: $902k
  • Dr. Toni Weinschenk Ph.D. (Age 50)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 58)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 47)
    Chief Operations Officer
  • Dr. Carsten Reinhardt M.D. (Age 57)
    Ph.D., Chief Development Officer
  • Dr. Rainer Kramer Ph.D. (Age 59)
    Chief Business Officer & Site Head Munich
  • Mr. Cedrik M. Britten M.D. (Age 48)
    Chief Medical Officer
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Mr. Kristijan Lasic
    Director of Accounting
  • Dr. Emmanuelle Schuler M.B.A.
    Ph.D., VP of Administration & Operations and US Site Head

IMTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immatics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings
or view top-rated stocks.

What is Immatics' stock price target for 2024?

2 analysts have issued 12 month price objectives for Immatics' stock. Their IMTX share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price.
View analysts price targets for IMTX
or view top-rated stocks among Wall Street analysts.

How have IMTX shares performed in 2024?

Immatics' stock was trading at $10.53 at the beginning of 2024. Since then, IMTX stock has increased by 4.7% and is now trading at $11.02.
View the best growth stocks for 2024 here
.

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our IMTX earnings forecast
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The firm earned $7.60 million during the quarter, compared to analysts' expectations of $13.28 million. Immatics had a negative net margin of 179.67% and a negative trailing twelve-month return on equity of 43.58%.

What ETFs hold Immatics' stock?

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

Who are Immatics' major shareholders?

Immatics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.50%), Price T Rowe Associates Inc. MD (2.76%), Price T Rowe Associates Inc. MD (2.76%), Vestal Point Capital LP (2.48%), Goldman Sachs Group Inc. (1.83%) and Goldman Sachs Group Inc. (1.83%).

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners